Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Short Interest Update

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totaling 2,256,450 shares, an increase of 28.5% from the December 31st total of 1,755,818 shares. Based on an average daily volume of 612,457 shares, the short-interest ratio is presently 3.7 days. Based on an average daily volume of 612,457 shares, the short-interest ratio is presently 3.7 days.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.6%

Shares of NYSE:FMS traded down $0.13 during trading on Monday, reaching $22.58. The stock had a trading volume of 430,741 shares, compared to its average volume of 681,934. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.94 and a fifty-two week high of $30.46. The business has a fifty day moving average price of $23.15 and a 200-day moving average price of $24.64. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45. The stock has a market cap of $13.09 billion, a P/E ratio of 16.48, a PEG ratio of 0.72 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. The company had revenue of $5.73 billion for the quarter, compared to the consensus estimate of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%. As a group, analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Large investors have recently made changes to their positions in the business. Pzena Investment Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 1.0% during the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after buying an additional 153,870 shares during the period. Todd Asset Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 5.2% during the third quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock valued at $34,319,000 after acquiring an additional 64,311 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 8.3% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 816,200 shares of the company’s stock worth $21,491,000 after purchasing an additional 62,700 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 26.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 373,961 shares of the company’s stock valued at $10,684,000 after purchasing an additional 78,956 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after purchasing an additional 248,477 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on FMS. The Goldman Sachs Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Truist Financial set a $28.00 target price on Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Bank of America downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Finally, Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 5th. Four equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.